GlassScriptPhysician profile
Eric Polo Moreno
NPI 1578235495
$6,288.73
in general payments reported to CMS, 2019-2025
31 companies · $2,218 in 2025
The $2,218 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $887 · 2023: $622 · 2024: $2,455 · 2025: $2,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,099 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,099.11 |
| Education | $195.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $1,139.28 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $1,012.29 | 2022-2025 | Tremfya |
| Abbvie INC. | $512.28 | 2022-2025 | |
| Pfizer INC. | $478.98 | 2023-2025 | |
| Genzyme Corporation | $454.83 | 2022-2025 | |
| Ucb, INC. | $311.01 | 2023-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $289.81 | 2022-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $288.81 | 2024-2025 | Sotyktu |
| Botanix Sb INC | $199.00 | 2025 | Sofdra |
| Incyte Corporation | $165.44 | 2022-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $163.45 | 2021-2025 | Libtayo |
| Amgen INC. | $159.87 | 2022-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $149.95 | 2021-2025 | Odomzo, Blu-U |
| Kerecis Limited | $146.44 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Journey Medical Corporation | $135.63 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $110.14 | 2025 | Vtama |
| Hill Dermaceuticals, INC. | $93.46 | 2022 | |
| Dermavant Sciences, INC. | $81.75 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $75.28 | 2023-2025 | |
| Leo Pharma INC. | $52.40 | 2023-2025 | Adbry |
| Mallinckrodt Hospital Products INC. | $34.43 | 2025 | Acthar |
| Organogenesis INC. | $32.33 | 2023 | Puraply |
| Verrica Pharmaceuticals INC. | $31.85 | 2025 | Ycanth |
| Epi Health, LLC | $30.39 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.32 | 2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.85 | 2024 | Siliq |
| Galderma Laboratories, L.P. | $22.04 | 2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $18.93 | 2022 | |
| Almirall LLC | $17.46 | 2021 | |
| Lilly USA, LLC | $16.25 | 2025 | Ebglyss, Taltz |
| Tempus Ai, INC | $13.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.